ArticleProstate cancer2015

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.

Ulka Vaishampayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.